Ask about this productRelated genes to: HOXA5 antibody
- Gene:
- HOXA5 NIH gene
- Name:
- homeobox A5
- Previous symbol:
- HOX1C, HOX1
- Synonyms:
- -
- Chromosome:
- 7p15.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-06-15
- Date modifiied:
- 2015-09-07
Related products to: HOXA5 antibody
Related articles to: HOXA5 antibody
- Mediastinal gray zone lymphoma (MGZL) is a rare B-cell lymphoma characterized by overlapping clinicopathologic and molecular features of primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (CHL). Under current WHO-HEMA5 and International Consensus Classification (ICC) frameworks, MGZL is restricted to EBV-negative lymphomas arising in the mediastinum. This review summarizes current evidence on epidemiology, clinical presentation, pathology, molecular characteristics, diagnostic challenges, and therapeutic approaches to MGZL, with data derived from retrospective series, limited prospective cohorts, and recent molecular studies. MGZL predominantly affects young adults and commonly presents with bulky mediastinal disease. Diagnosis is challenging due to transitional morphology, pleomorphic Reed-Sternberg-like cells, and variable expression of B-cell and activation markers. Molecular studies demonstrate shared alterations with PMBL and CHL, including 9p24.1 (JAK2/PD-L1/PD-L2) gains, while additional reported features such as HOXA5 hypomethylation and MYC copy number gains support its biological distinctiveness, although evidence remains limited. Frontline treatment commonly involves intensive chemoimmunotherapy regimens such as DA-EPOCH-R; however, outcomes remain inferior to PMBL and CHL, with 5-year overall survival rates of approximately 40-60%. Relapsed or refractory disease frequently requires salvage chemotherapy and autologous stem cell transplantation. Immune-based therapies, including brentuximab vedotin and PD-1 inhibitors, have shown promising activity, particularly in combination. MGZL remains a diagnostically challenging and therapeutically complex lymphoma with inferior outcomes compared with related mediastinal lymphomas. Advances in molecular profiling and immunotherapy offer promising avenues toward more personalized treatment; however, prospective clinical trials and international collaboration are urgently needed to establish evidence-based management strategies for this rare entity. - Source: PubMed
Publication date: 2025/12/31
Zorlu TugbaSeyhan MertAbdullayeva NigarUlas TurgaySinan Dal Mehmet - Allergic asthma pathogenesis encompasses systemic immune, metabolic, and epithelial barrier dysfunction; however, minimally invasive tools to longitudinally explore these processes remain limited. - Source: PubMed
Publication date: 2026/01/06
Liu DanielKim MadelineDel Duca EsterBar JonathanLau MeganLargen JosephAgache IoanaGuttman-Yassky Emma - As dementia cases continue to rise, effective prevention strategies are urgently needed. However, objective biomarkers that directly reflect lifestyle factors remain limited. Life's Essential 8 (LE8) is a composite of modifiable cardiovascular health metrics, and lower LE8 has been consistently associated with increased risk of dementia. In this study, we aimed to identify DNA methylation biomarkers associated with LE8 scores and investigate their relevance for dementia risk. - Source: PubMed
Publication date: 2025/12/29
Lukacsovich DavidWang LiyongYoung Juan IZhang WeiGomez LissetteSchmidt Michael AGardener HannahAgudelo ChristianDueker NicoleElfassy TaliGibbs CarlaScott Sadeaqua SMartin Eden RKunkle Brian WChen X StevenBlanton SusanRundek TatjanaWang Lily - The management and prevention of childhood asthma remain significant challenges. Mendelian randomization (MR) has emerged as a valuable tool for identifying novel therapeutic targets. In response, we conducted a comprehensive, druggable genome-wide MR analysis to elucidate potential therapeutic targets for childhood asthma. Our study integrated genomic data concerning druggable targets, expression quantitative trait loci (eQTLs), and results from genome-wide association studies on childhood asthma. Employing the MR technique, we explored the putative causal links between genes that are targets for drugs and the development of childhood asthma. To validate these causal associations, we utilized reverse MR analyses along with colocalization techniques. Moreover, we performed enrichment analysis, mapped protein interaction networks, and executed drug prediction algorithms and molecular docking studies. These methodologies were applied to gain critical insights that could guide the development of more potent and precise therapeutic agents. We identified 35 druggable genes significantly associated with childhood asthma (including BLVRA, SLC9A3, LYZ, SRPK1, HOXA5, LYVE1, S100A9, ADORA1, RPL13, IL7R, SLFN11, SHMT1, CLN8, TOP1MT, LPAR5, RNASET2, ANK1, H6PD, DSP, CDC25B, VWF, ITK, CACNG6, ITGB7, S100A8, ADAM12, ST14, BMP6, HK2, SYK, ABCA1, ULK4, KBTBD2, SLCO4C1), with BLVRA showing promise as a target. Our research suggests that BLVRA may be a promising target for childhood asthma treatment, aiding in the prioritization of drug development for childhood asthma. - Source: PubMed
Bi JunjieLiu XueZhang JingjingZhao Liqun - Transcranial magnetic stimulation (TMS) is an established treatment for major depressive disorder (MDD), yet response rates remain suboptimal and biomarkers predictive of treatment outcomes are currently lacking. Recently, DNA methylation (DNAm) has shown promise as an epigenetic predictor of antidepressant and electroconvulsive therapy treatment outcomes but no study to our knowledge has characterized DNAm profiles of treatment outcomes in the context of TMS. Here, we present the first genome-scale DNAm analysis of TMS outcomes in patients with treatment-resistant depression (TRD). - Source: PubMed
Publication date: 2025/11/12
Dahrendorff JanPages KennethCurrier GlennSarker Mainul HasanGraham ZacharyLouis-Jacques Adetola FDagne GetachewUddin Monica